Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
8.45
-0.04 (-0.41%)
Nov 18, 2025, 3:28 PM EST - Market open
Intellia Therapeutics Revenue
Intellia Therapeutics had revenue of $13.78M in the quarter ending September 30, 2025, with 51.27% growth. This brings the company's revenue in the last twelve months to $57.53M, up 33.52% year-over-year. In the year 2024, Intellia Therapeutics had annual revenue of $57.88M with 59.55% growth.
Revenue (ttm)
$57.53M
Revenue Growth
+33.52%
P/S Ratio
15.46
Revenue / Employee
$142,749
Employees
403
Market Cap
978.18M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 57.88M | 21.60M | 59.55% |
| Dec 31, 2023 | 36.28M | -15.85M | -30.40% |
| Dec 31, 2022 | 52.12M | 19.07M | 57.69% |
| Dec 31, 2021 | 33.05M | -24.94M | -43.01% |
| Dec 31, 2020 | 57.99M | 14.89M | 34.55% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
NTLA News
- 8 days ago - Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy - GlobeNewsWire
- 9 days ago - Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema - GlobeNewsWire
- 11 days ago - Intellia Therapeutics, Inc. (NTLA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 19 days ago - US FDA places clinical hold on Intellia's two gene-editing treatment trials - Reuters
- 22 days ago - Intellia Therapeutics, Inc. (NTLA) Discusses Safety Event and Protocol Pause in MAGNITUDE Clinical Trials of Nex-Z Transcript - Seeking Alpha
- 22 days ago - Intellia pauses late-stage trials of gene-editing treatment after serious liver event - Reuters
- 22 days ago - Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z) - GlobeNewsWire
- 25 days ago - Crispr And Intellia: Advancing In Vivo Gene Editing As 2025 Results Strengthen Investment Outlook - Seeking Alpha